A New Jersey compounding pharmacy has halted operations after health officials learned that some sterile compounded products delivered to a Connecticut hospital appeared cloudy and possibly contaminated.
Med Prep Consulting Inc. is now at the center of an investigation by the Connecticut departments of Consumer Protection and Public Health, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention.
The investigation comes less than six months after some medications packaged and marketed by the New England Compounding Center in Massachusetts were found to be the cause of a nationwide fungal meningitis outbreak.
State officials have advised any Connecticut acute care hospitals of the potential contamination and have  requested that hospitals sequester any medications they obtained from Med Prep while the investigation is underway.
Jewel Mullen, commissioner of the Department of Public Health, said in a statement that the state is working with hospital officials to ensure that patients who may have received the potentially contaminated products are notified and are closely monitored. The hospital or hospitals in question were not identified.
The New Jersey State Board of Pharmacy announced March 15 that Med Prep had temporarily halted all pharmacy operations after it issued a voluntary recall of bags of magnesium sulfate intravenous solution.
